210963-95-4

Basic information

• Product Name: 6-Pyrrolidin-1-yl-nicotinic acid
• Synonyms: 3-Pyridinecarboxylic acid, 6-(1-pyrrolidinyl)-;2-(Pyrrolidin-1-yl)pyridine-5-carboxylic acid;6-(1-Pyrrolidinyl)-3-pyridinecarboxylic acid
• CAS NO: 210963-95-4
• Molecular Formula: C₁₀H₁₂N₂O₂
• Molecular Weight: 192.22
• Product Categories: pharmacetical;Carboxylic Acids;Pyridines
• Mol File: 210963-95-4.mol
• Article Data: 4

Chemical Properties

• Melting Point: 259-261°
• Boiling Point: 408.3°C at 760 mmHg
• Flash Point: 200.733°C
• Appearance: /
• Density: 1.284g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 6-Pyrrolidin-1-yl-nicotinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Pyrrolidin-1-yl-nicotinic acid(210963-95-4)
• EPA Substance Registry System: 6-Pyrrolidin-1-yl-nicotinic acid(210963-95-4)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 210963-95-4(Hazardous Substances Data)

Usage

General Description

6-Pyrrolidin-1-yl-nicotinic acid is a compound that consists of a pyrrolidinyl group attached to a nicotinic acid moiety. It is a potential drug candidate with various pharmacological activities, including anti-inflammatory and antioxidant properties. This chemical has been studied for its potential use in the treatment of neurodegenerative diseases and various other disorders. Its unique structure and potential therapeutic benefits make it an interesting target for further research and development in the field of pharmaceuticals.

InChI:InChI=1/C10H12N2O2/c13-10(14)8-3-4-9(11-7-8)12-5-1-2-6-12/h3-4,7H,1-2,5-6H2,(H,13,14)

Upstream product

• 897399-74-5 6-pyrrolidin-1-yl-nicotinic acid ethyl ester 
• 123-75-1 pyrrolidine 
• 5326-23-8 6-Chloro-3-pyridinecarboxylic acid 

Downstream Products

• 1232028-02-2 N-{2-[4-(5-fluoro-2-trifluoromethyl-benzoyl)-piperazin-1-yl]-2-oxo-ethyl}-6-pyrrolidin-1-yl-nicotinamide 

Relevant articles and documents

Permeability of novel 4′-N-substituted (aminomethyl) benzoate-7-substituted nicotinic acid ester derivatives of scutellarein in Caco-2 cells and in an in vitro model of the blood-brain barrier

A series of 4′-N-substituted (aminomethyl) benzoate-7-substituted nicotinic acid ester derivatives of scutellarein was designed and synthesized. Evaluation of physiochemical properties showed that the newly designed compounds had greater chemical stability and aqueous solubility than scutellarin or scutellarein. The permeabilities (Papp AP to BL) of compounds 7b and 7e in Caco-2 cells were 5.9-fold and 3.7-fold higher than that of scutellarin, and 3.7-fold and 2.4-fold higher than that of scutellarein. The permeabilities (Papp AP to BL) of compounds 7b and 7e in an in vitro model of the blood–brain barrier were 9.7-fold and 5.9-fold higher than that of scutellarin, and 9.2-fold and 5.6-fold higher than that of scutellarein.

3-Nitro-4-amino benzoic acids and 6-amino nicotinic acids are highly selective agonists of GPR109b

A series of 3-nitro-4-substituted-aminobenzoic acids were prepared and found to act as potent and highly selective agonists of the orphan human GPCR GPR109b, a low affinity receptor for niacin. No activity was observed at the closely homologous high affinity niacin receptor, GPR109a. A second series, comprising 6-amino-substituted nicotinic acids was, also prepared and several analogues showed comparable activity to the nitroaryl series.